Peer2Peer: The Podcast

This episode of ‘Peer2Peer: The Podcast’, focuses on clinical performance and results from studies conducted with OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%.  in cataract surgery. The episode, featuring Dr. Denise Visco and Dr. Steven Silverstein, highlights the potential advantages of OMIDRIA in cataract surgery shown by rigorous clinical trials, including improved patient compliance and reduced reliance on pain medications, without increasing the risk of complications.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner or other  products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.
 
Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300032 07/23
 
IMPORTANT SAFETY INFORMATION 
OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.

In this second episode of ‘Peer2Peer: The Podcast’ focused on OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3, host Dr Arjan Hura, discusses the use of OMIDRIA with Dr. Cathleen McCabe and Dr. Neda Shamie. They highlight the challenges faced by surgeons who suffer from high workloads and how OMIDRIA can help mitigate some of the risks associated with stress in case of complications. Additionally, they explain the benefits of using OMIDRIA with high-risk patients, and the reasons why they often apply it in less complicated cases as well.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.
 
Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300031 07/23
 
IMPORTANT SAFETY INFORMATION 
OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA: https://www.omidriahcp.com/documents/8/OMIDRIA-Prescribing-Information.pdf
 

This episode of ‘Peer2Peer: The Podcast’ is the first from a series of four episodes dedicated to OMIDRIA®(phenylephrine and ketorolac intraocular solution) 1%/0.3%. Dr Arjan Hura, together with top surgeons Gary Foster, Rebecca Metzinger, Denise Visco, Neda Nikpoor, Inder Paul Singh, Kendall Donaldson, Keith Walter and Mitch Jackson share their thoughts and experience on the use of OMIDRIA in cataract surgery. They highlight the benefits of incorporating OMIDRIA, including an improved surgeon, practice, and patient perioperative experience.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner or other products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.
Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300030 07/23
 
IMPORTANT SAFETY INFORMATION 
OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA: https://www.omidriahcp.com/documents/8/OMIDRIA-Prescribing-Information.pdf
 

Recorded at ASCRS, Professor Oliver Findl and Prof David Chang discuss their collective dedication to promoting sustainability in the field of ophthalmology. They delve into the various initiatives, best practices, and offer a visionary outlook, ultimately illuminating the path toward a future where sustainable eye surgery thrives.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner is a proprietary mark of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Recorded at ASCRS, Dr Ben LaHood chats with Professor Graham Barrett who has made an extensive contribution to ophthalmology including Rayner’s RayOne EMV enhanced monofocal IOL.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Recorded at ASCRS, Dr Ben LaHood and Dr Damien Gatinel dive deeply into advanced IOL optics and discuss the bench testing Gatinel has performed across a large number of the IOLs currently on the market. The results of this work empower ophthalmic surgeons to better predict the performance of different IOLs based on key factors such as asphericity, aspheric aberration (positive or negative), thickness, multifocality, aperture effect, lens placement and more.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Dr Ben LaHood and Ms Lucia Pelosini discuss the effective strategies for managing astigmatism. They delve into key aspects such as patient assessment, selection processes, and the treatment of astigmatism in regular and irregular eyes. They also analyse the latest data on the RayOne EMV Toric and share invaluable insights to help achieve optimal outcomes with toric IOLs.
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Mr Alastair Stuart and Dr Ben LaHood explore the advancements in technology that enable modified monovision. The discussion encompasses the utilisation of positive and negative spherical aberration, a comprehensive comparison between enhanced monofocal and trifocal IOLs, and valuable insights for surgeons striving to deliver optimal blended vision to patients who desire reduced reliance on eyeglasses. 
 
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

Mr Alastair Stuart and Dr Ben LaHood explore the advancements in technology that enable modified monovision. The discussion encompasses the utilisation of positive and negative spherical aberration, a comprehensive comparison between enhanced monofocal and trifocal IOLs, and valuable insights for surgeons striving to deliver optimal blended vision to patients who desire reduced reliance on eyeglasses. 
 
 
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539

In this episode, Rayner’s Vice President of Marketing, Chris Willis, is joined by Marketing Director for the Americas, Sam van Roon, and Sr. Director and OMIDRIA Brand Lead, Nicolee Schulze to discuss what listeners can expect from Rayner at ASCRS this year, including the US launch of HASA OPTIX and RayPRO+, and new outcome data on Rayner products that will be presented on the podium.
This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries.
© 2023 Rayner Group, all rights reserved. Rayner, RayOne, RayPRO and OMIDRIA are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539